$1.57
1.88% yesterday
Nasdaq, Sep 16, 10:02 pm CET
ISIN
US9290331084
Symbol
VOR

Vor Biopharma Inc Stock price

$1.57
-0.47 23.04% 1M
+0.71 82.49% 6M
+0.46 41.44% YTD
+0.56 55.45% 1Y
-3.14 66.67% 3Y
-16.43 91.28% 5Y
-16.43 91.28% 10Y
-16.43 91.28% 20Y
Nasdaq, Closing price Tue, Sep 16 2025
-0.03 1.88%
ISIN
US9290331084
Symbol
VOR
Industry

Key metrics

Basic
Market capitalization
$202.7m
Enterprise Value
$2.1m
Net debt
positive
Cash
$200.6m
Shares outstanding
125.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
67.7%
Return on Equity
-121.0%
ROCE
-250.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-362.8m | $-125.6m
EBIT
$-367.4m | $-204.3m
Net Income
$-1.7b | $-157.6m
Free Cash Flow
$-114.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-199.3% | -6.7%
EBIT
-194.4% | -68.6%
Net Income
-1,309.5% | -34.8%
Free Cash Flow
-8.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-13.3
FCF per Share
$-0.9
Short interest
41.3%
Employees
154
Rev per Employee
$0.0
Show more

Is Vor Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Vor Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vor Biopharma Inc forecast:

4x Buy
44%
5x Hold
56%

Analyst Opinions

9 Analysts have issued a Vor Biopharma Inc forecast:

Buy
44%
Hold
56%

Financial data from Vor Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
6% 6%
-
- Research and Development Expense 335 335
254% 254%
-
-363 -363
199% 199%
-
- Depreciation and Amortization 4.58 4.58
28% 28%
-
EBIT (Operating Income) EBIT -367 -367
194% 194%
-
Net Profit -1,664 -1,664
1,309% 1,309%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vor Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vor Biopharma Inc Stock News

Neutral
GlobeNewsWire
4 days ago
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.
Neutral
GlobeNewsWire
14 days ago
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D.
Neutral
GlobeNewsWire
20 days ago
Results reinforce telitacicept's potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), ach...
More Vor Biopharma Inc News

Company Profile

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Bob Ang
Employees 154
Founded 2015
Website www.vorbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today